Published in Cancer Res on April 01, 2005
STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer (2009) 15.45
Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci U S A (2007) 4.05
Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res (2007) 3.53
Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci U S A (2008) 2.99
Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. Genes Dev (2008) 2.61
Targeting STAT3 in cancer: how successful are we? Expert Opin Investig Drugs (2009) 2.58
Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol (2012) 2.46
Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer. Breast Cancer Res (2007) 2.32
Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia. EMBO Mol Med (2010) 2.23
Normal and disease-related biological functions of Twist1 and underlying molecular mechanisms. Cell Res (2011) 1.99
Twist is transcriptionally induced by activation of STAT3 and mediates STAT3 oncogenic function. J Biol Chem (2008) 1.98
A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells. Neoplasia (2010) 1.70
STAT3 is necessary for proliferation and survival in colon cancer-initiating cells. Cancer Res (2011) 1.63
The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis. Neoplasia (2013) 1.58
Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3. Proc Natl Acad Sci U S A (2006) 1.53
Antitumorigenic potential of STAT3 alternative splicing modulation. Proc Natl Acad Sci U S A (2011) 1.48
STAT3 induces transcription of the DNA methyltransferase 1 gene (DNMT1) in malignant T lymphocytes. Blood (2006) 1.46
Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells. Mol Cancer Ther (2010) 1.31
STAT3 Target Genes Relevant to Human Cancers. Cancers (Basel) (2014) 1.29
Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cells. BMC Cancer (2007) 1.20
Withaferin A inhibits activation of signal transducer and activator of transcription 3 in human breast cancer cells. Carcinogenesis (2010) 1.19
Differential interleukin-6/Stat3 signaling as a function of cellular context mediates Ras-induced transformation. Breast Cancer Res (2010) 1.17
Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development. Breast Cancer Res (2012) 1.14
STAT3 regulation of glioblastoma pathogenesis. Curr Mol Med (2009) 1.13
Mitochondrial localized Stat3 promotes breast cancer growth via phosphorylation of serine 727. J Biol Chem (2013) 1.12
Stat3 mediates expression of autotaxin in breast cancer. PLoS One (2011) 1.03
Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice. Invest New Drugs (2011) 1.03
A mutual activation loop between breast cancer cells and myeloid-derived suppressor cells facilitates spontaneous metastasis through IL-6 trans-signaling in a murine model. Breast Cancer Res (2013) 1.02
Suppression of Her2/neu expression through ILK inhibition is regulated by a pathway involving TWIST and YB-1. Oncogene (2010) 1.01
Surgery-induced wound response promotes stem-like and tumor-initiating features of breast cancer cells, via STAT3 signaling. Oncotarget (2014) 0.99
Signal transducers and activators of transcription 3 (STAT3) directly regulates cytokine-induced fascin expression and is required for breast cancer cell migration. J Biol Chem (2011) 0.98
Inhibition of STAT3 signaling targets both tumor-initiating and differentiated cell populations in prostate cancer. Oncotarget (2014) 0.97
The small molecule, LLL12, inhibits STAT3 phosphorylation and induces apoptosis in medulloblastoma and glioblastoma cells. PLoS One (2011) 0.96
Constitutive activation of STAT3 in breast cancer cells: A review. Int J Cancer (2015) 0.96
Targeting CD44-STAT3 signaling by Gemini vitamin D analog leads to inhibition of invasion in basal-like breast cancer. PLoS One (2013) 0.96
Mesenchymal Stem Cells Overexpressing IFN-β Inhibit Breast Cancer Growth and Metastases through Stat3 Signaling in a Syngeneic Tumor Model. Cancer Microenviron (2010) 0.95
Caveolin-1 upregulation mediates suppression of primary breast tumor growth and brain metastases by stat3 inhibition. Cancer Res (2011) 0.95
The role of regulatory T cells in cancer. Immune Netw (2009) 0.93
TCPTP regulates SFK and STAT3 signaling and is lost in triple-negative breast cancers. Mol Cell Biol (2012) 0.93
Crosstalk of Sp1 and Stat3 signaling in pancreatic cancer pathogenesis. Cytokine Growth Factor Rev (2012) 0.92
Noncanonical NF-κB activation mediates STAT3-stimulated IDO upregulation in myeloid-derived suppressor cells in breast cancer. J Immunol (2014) 0.92
The CXCR4 antagonist AMD3465 regulates oncogenic signaling and invasiveness in vitro and prevents breast cancer growth and metastasis in vivo. PLoS One (2013) 0.91
A small molecule, LLL12 inhibits constitutive STAT3 and IL-6-induced STAT3 signaling and exhibits potent growth suppressive activity in human multiple myeloma cells. Int J Cancer (2011) 0.90
A novel small molecular STAT3 inhibitor, LY5, inhibits cell viability, cell migration, and angiogenesis in medulloblastoma cells. J Biol Chem (2014) 0.89
Cucurbitacin I induces protective autophagy in glioblastoma in vitro and in vivo. J Biol Chem (2014) 0.87
Berberine suppresses tumorigenicity and growth of nasopharyngeal carcinoma cells by inhibiting STAT3 activation induced by tumor associated fibroblasts. BMC Cancer (2013) 0.85
Genome-wide screen identified let-7c/miR-99a/miR-125b regulating tumor progression and stem-like properties in cholangiocarcinoma. Oncogene (2015) 0.85
Increased levels of active c-Src distinguish invasive from in situ lobular lesions. Breast Cancer Res (2009) 0.84
Mouse mammary tumors display Stat3 activation dependent on leukemia inhibitory factor signaling. Breast Cancer Res (2007) 0.84
XZH-5 inhibits STAT3 phosphorylation and enhances the cytotoxicity of chemotherapeutic drugs in human breast and pancreatic cancer cells. PLoS One (2012) 0.84
Simultaneous siRNA targeting of Src and downstream signaling molecules inhibit tumor formation and metastasis of a human model breast cancer cell line. PLoS One (2011) 0.83
Increased metastasis with loss of E2F2 in Myc-driven tumors. Oncotarget (2015) 0.82
Increased Twist expression in advanced stage of mycosis fungoides and Sézary syndrome. J Cutan Pathol (2012) 0.81
Single cell cytometry of protein function in RNAi treated cells and in native populations. BMC Cell Biol (2008) 0.81
Humanized Lewis-Y specific antibody based delivery of STAT3 siRNA. ACS Chem Biol (2011) 0.81
Persistent GP130/STAT3 Signaling Contributes to the Resistance of Doxorubicin, Cisplatin, and MEK Inhibitor in Human Rhabdomyosarcoma Cells. Curr Cancer Drug Targets (2016) 0.79
CXCR7 expression in nasopharyngeal carcinoma tissues correlates with disease severity. Int J Clin Exp Med (2015) 0.78
Loss of STAT3 in Lymphoma Relaxes NK Cell-Mediated Tumor Surveillance. Cancers (Basel) (2014) 0.77
Twist1 regulates keratinocyte proliferation and skin tumor promotion. Mol Carcinog (2015) 0.76
Multiple biological functions of Twist1 in various cancers. Oncotarget (2017) 0.75
Anti-tumor effect of inhibition of IL-6 signaling in mucoepidermoid carcinoma. Oncotarget (2015) 0.75
MicroRNA and Transcription Factor Gene Regulatory Network Analysis Reveals Key Regulatory Elements Associated with Prostate Cancer Progression. PLoS One (2016) 0.75
Mechanism of action of selective inhibitors of IL-6 induced STAT3 pathway in head and neck cancer cell lines. J Chem Biol (2017) 0.75
Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell (2006) 10.10
Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet (2003) 3.38
Janus kinase 2: a critical target in chronic myelogenous leukemia. Cancer Res (2006) 1.99
Tissue-resident stem cells promote breast cancer growth and metastasis. Carcinogenesis (2009) 1.92
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest (2013) 1.72
AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res (2005) 1.61
Jak2 is involved in c-Myc induction by Bcr-Abl. Oncogene (2002) 1.54
Inhibition of lipocalin 2 impairs breast tumorigenesis and metastasis. Cancer Res (2009) 1.43
Alternative splicing disrupts a nuclear localization signal in spleen tyrosine kinase that is required for invasion suppression in breast cancer. Cancer Res (2003) 1.41
Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. Blood (2013) 1.14
Multiplexed volumetric bar-chart chip for point-of-care diagnostics. Nat Commun (2012) 1.13
Destabilization of Bcr-Abl/Jak2 Network by a Jak2/Abl Kinase Inhibitor ON044580 Overcomes Drug Resistance in Blast Crisis Chronic Myelogenous Leukemia (CML). Genes Cancer (2010) 1.05
Aurora kinase-A inactivates DNA damage-induced apoptosis and spindle assembly checkpoint response functions of p73. Cancer Cell (2012) 1.02
Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course. Cancer (2002) 0.98
The c-Myc Oncoprotein Interacts with Bcr. Curr Biol (2003) 0.95
BCR-ABL1 mediates up-regulation of Fyn in chronic myelogenous leukemia. Blood (2008) 0.94
Relationships of lipocalin 2 with breast tumorigenesis and metastasis. J Cell Physiol (2011) 0.94
AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. Cancer (2005) 0.88
Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukaemia cells. J Cell Mol Med (2009) 0.86
A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition. Genes Cancer (2010) 0.85
Bcr and Abl interaction: oncogenic activation of c-Abl by sequestering Bcr. Cancer Res (2003) 0.85
Inhibition of the Bcr-Abl oncoprotein by Bcr requires phosphoserine 354. Cancer Res (2002) 0.84
Preparation and application of polyclonal and monoclonal sequence-specific anti-phosphoamino acid antibodies. Curr Protoc Protein Sci (2004) 0.83
Inhibition of the NADPH oxidase regulates heme oxygenase 1 expression in chronic myeloid leukemia. Cancer (2011) 0.80
WITHDRAWN: Requirement of lipocalin 2 in breast cancer. Adv Enzyme Regul (2009) 0.75